Saturday 17 October 2026
Export IRWD’s income statement to Excel — free account
Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.
3.50
0.27
−7.16%
Follow IRWD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 3 | 6 | 5 | 7 | 6 | 2 | 3 | 4 |
P/E ratio |
21.38 | 0.00 | 0.00 | 10.76 | 3.58 | 17.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.84 | 2.01 | 4.36 | 4.61 | 4.57 | 4.66 | 4.85 | 3.82 | 6.39 | 6.59 |
Altman Z-Score |
(3.75) | (3.76) | (9.54) | 3.62 | 2.68 | 1.06 | (0.11) | (5.13) | (0.25) | 0.01 |
P/FCF ratio |
4.29 | 6.82 | 10.53 | 6.92 | 7.23 | 10.87 | 545.92 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(11.97) | (11.79) | (26.28) | 5.50 | 3.29 | (1.26) | (6.59) | (16.16) | (4.54) | (3.18) |
P/Operating CF |
7.31 | 46.32 | 53.83 | 23.92 | 29.30 | 35.25 | 75.30 | 142.87 | (206.82) | (94.04) |
Beneish M-Score |
(4.20) | (4.32) | (15.29) | (2.91) | (0.19) | (3.08) | (1.25) | (4.75) | (1.96) | (1.65) |
P/B ratio |
0.00 | 0.00 | 0.00 | 2.90 | 3.12 | 28.99 | 0.00 | 0.00 | 193.50 | 27.05 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 2.91 | 3.13 | 29.36 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.09 | 3.98 | 5.73 | 3.98 | 4.21 | 4.84 | 5.39 | 4.51 | 6.97 | 6.81 |
EV/EBITDA |
9.11 | 14.72 | 0.00 | 6.50 | 7.46 | 12.87 | 18.36 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
7.20 | 13.52 | 13.82 | 5.98 | 6.66 | 11.16 | 215.15 | (22.07) | (20.65) | (71.94) |
EV/FCF |
7.20 | 13.54 | 13.84 | 5.98 | 6.66 | 11.29 | 606.61 | (22.45) | (20.11) | (62.37) |
Quick Ratio |
1.08 | 4.39 | 0.80 | 30.28 | 4.55 | 15.13 | 7.22 | 2.14 | 4.60 | 4.06 |
Current Ratio |
1.13 | 4.69 | 0.84 | 30.58 | 4.61 | 15.41 | 7.50 | 2.23 | 4.72 | 4.17 |
Net Debt/EBITDA |
3.68 | 5.21 | (0.64) | (1.03) | (0.64) | 0.47 | 1.84 | (1.73) | (66.00) | (1.66) |
Debt/Assets |
147.31% | 166.42% | 148.14% | 36.28% | 41.96% | 77.47% | 101.55% | 124.63% | 66.06% | 52.52% |
Debt/Equity |
(2.23) | (1.94) | (2.02) | 0.61 | 0.78 | 6.92 | (4.39) | (2.11) | 40.63 | 5.59 |
Asset Turnover |
0.79 | 0.86 | 0.56 | 0.37 | 0.49 | 0.81 | 1.17 | 0.74 | 0.45 | 0.41 |
Operating CF/Net income |
5.29 | 117.67 | (0.18) | 1.56 | 0.50 | 1.59 | 0.50 | 0.25 | 0.86 | 0.32 |
Capex/Depreciation |
(0.02) | (0.07) | (0.17) | (0.10) | (0.17) | (0.52) | (1.24) | 0.10 | (0.21) | (9.23) |
Interest Coverage |
3.01 | 2.82 | (43.71) | 32.95 | 7.46 | 4.85 | 3.28 | (3.99) | (0.42) | (1.32) |
| (8.53%) | (0.27%) | (654.88%) | 27.83% | 158.09% | (693.71%) | (14.85%) | 302.77% | (305.46%) | (100.97%) | |
| 6.42% | 0.21% | (127.54%) | 15.72% | 62.68% | 22.07% | 5.85% | (60.22%) | (17.78%) | (12.30%) | |
ROIC |
57.33% | 29.99% | (227.77%) | 39.69% | 31.74% | 67.89% | 54.61% | (218.71%) | (5.09%) | (24.14%) |
Return on Tangible Assets |
67.91% | 0.59% | 2,692.16% | 22.99% | 89.40% | 22.47% | 7.73% | (182.69%) | (44.49%) | (26.39%) |
Average Days of Receivables |
57.61 | 85.05 | 106.45 | 102.64 | 100.60 | 114.65 | 99.89 | 85.24 | 100.54 | 86.41 |
Research and Development Expense of Revenue |
32.12% | 31.71% | 273.65% | 10.78% | 17.02% | 22.61% | 26.85% | 29.15% | 29.55% | 50.92% |
Selling, General and Administrative Expense of Revenue |
27.78% | 41.06% | 35.76% | 28.25% | 26.86% | 35.94% | 40.25% | 63.37% | 77.51% | 63.25% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.24 |
Share Based Compensation of Revenue |
5.82% | 8.49% | 7.23% | 6.59% | 5.39% | 8.00% | 7.30% | 11.69% | 10.36% | 10.67% |
Graham Net Nets |
(0.71) | (0.67) | (0.30) | 0.18 | 0.12 | 0.00 | (0.09) | (0.20) | (0.15) | (0.15) |
Graham Number |
0.00 | 0.20 | 17.98 | 10.41 | 16.55 | 2.43 | 1.17 | 7.32 | 0.00 | 0.00 |
Earnings Yield |
4.68% | (0.02%) | (51.97%) | 9.29% | 27.96% | 5.88% | (0.77%) | (21.31%) | (6.25%) | (4.50%) |
Free Cash Flow Yield |
23.29% | 14.67% | 9.50% | 14.45% | 13.83% | 9.20% | 0.18% | (5.26%) | (5.43%) | (1.66%) |
Revenue per Share |
1.83 | 2.21 | 2.85 | 2.66 | 2.55 | 2.44 | 2.75 | 2.27 | 2.00 | 1.89 |
Operating CF per Share |
0.79 | 0.65 | 1.18 | 1.77 | 1.61 | 1.06 | 0.07 | (0.46) | (0.68) | (0.18) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.04) | 0.01 | (0.02) | (0.72) |
Free Cash Flow per Share |
0.78 | 0.65 | 1.18 | 1.77 | 1.61 | 1.05 | 0.02 | (0.46) | (0.69) | (0.90) |
Cash per Share |
1.33 | 0.56 | 0.59 | 4.26 | 3.83 | 2.29 | 1.14 | 1.14 | 1.49 | 2.11 |
Shareholders Equity per Share |
(1.62) | (1.89) | (2.23) | 4.23 | 3.73 | 0.39 | (0.60) | (1.29) | 0.07 | 0.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.62) | (1.89) | (2.23) | 4.23 | 3.73 | 0.39 | (0.60) | (1.29) | 0.07 | 0.46 |
Free Cash Flow |
127.01 | 103.41 | 183.15 | 273.63 | 261.63 | 166.99 | 3.80 | (69.67) | (103.42) | (129.91) |
Working Capital |
31.96 | 143.52 | (42.81) | 755.10 | 583.53 | 463.67 | 265.92 | 146.91 | 245.57 | 289.05 |
Capital Expenditures |
(0.03) | (0.14) | (0.27) | (0.14) | (0.26) | (1.84) | (6.92) | 1.21 | (2.67) | (103.98) |
Net Current Asset Value |
(384.56) | (469.87) | (584.08) | 332.49 | 224.21 | (0.76) | (189.15) | (261.99) | (284.23) | (262.92) |
EV/EBIT |
9.29 | 15.03 | 0.00 | 6.53 | 7.51 | 13.19 | 19.21 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.38 |
Price to Operating Income |
5.54 | 7.57 | 0.00 | 7.57 | 8.15 | 12.70 | 17.29 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.55 | 0.45 | 0.28 | 0.23 | 0.20 | 0.40 | 0.45 | 1.56 | 0.73 | 0.55 |
Cash ROIC |
23.59% | 27.86% | 41.28% | 16.01% | 15.39% | 19.41% | 0.77% | (17.78%) | (16.38%) | (17.44%) |
Accounts Receivable Turnover |
4.60 | 3.33 | 3.62 | 3.58 | 3.50 | 3.25 | 4.32 | 4.25 | 4.06 | 4.59 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.02 | 2.34 | 2.12 | 1.13 | 0.14 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 4.84 | (302.22) | (922.56) | 21.03 | 0.62 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.93 | 83.89 | 165.96 | 305.00 | 3,459.10 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 9.91 | (8.98) | 14.05 | 211.22 |
Average Receivables |
64.32 | 105.50 | 122.29 | 114.75 | 118.20 | 119.80 | 99.10 | 81.55 | 73.51 | 59.69 |
Average Payables |
2.51 | 4.98 | 4.16 | 0.71 | 0.80 | 3.07 | 10.19 | 15.42 | 16.83 | 13.15 |
Average Inventory |
— | — | — | — | — | 0.65 | (0.08) | (0.04) | 0.91 | 3.02 |
Average Assets |
373.90 | 410.99 | 785.80 | 1,113.72 | 843.08 | 480.99 | 367.40 | 468.86 | 657.75 | 664.47 |
Average Common Equity |
(281.58) | (323.81) | 153.04 | 629.14 | 334.28 | (15.31) | (144.81) | (93.26) | 38.28 | 80.92 |
Columns are period end dates